Item no. |
PTM-1014 |
Manufacturer |
PTM Biolabs
|
Amount |
100 ul |
Format |
Lyophilized powder |
Applications |
WB |
Specific against |
Human (Homo sapiens) |
Host |
Rabbit |
Isotype |
IgG |
Conjugate/Tag |
Unconjugated |
Alias |
H3-3A, H3.3A, H3F3, H3F3A, H3-3B, H3.3B, H3F3B |
Shipping condition |
Room temperature |
Available |
|
Manufacturer - Type |
Primary Antibodies |
Manufacturer - Category |
Histone & Histone Modification Antibodies |
Manufacturer - Targets |
Histone H3.3 |
Shipping Temperature |
Ambient temperature |
Storage Conditions |
Store at -20°C. Avoid freeze/thaw cycles. |
Molecular Weight |
15 |
Manufacturer - Research Area |
Epigenetics |
Product description |
K36M mutant of histone H3.3 is an "oncohistone" identified in more than 90% of chondroblastoma, a rare type of benign tumor caused by cartilage-producing cells. The mutant inhibits at least two H3K36 methyltransferases MMSET/WHSC1 and SETD2, triggering a depletion of H3K36 methylation and an increase of H3K27 trimethylation. H3.3K36M mutant proteins further alters expression of various genes including BMP2 that regulate oncogenesis and chondrogenesis. Chondrocytes expressing H3.3K36M exhibit several cancer-associated cellular phenotypes, including increased ability to form colonies, resistance to staurosporine-induced apoptosis, and defects in differentiation. |
Purification Method |
Protein A and immunogen affinity purified |
Manufacturer - Specificity |
Anti-Histone H3.3 (Mutated K36M) Rabbit pAb detects endogenous levels of K36M mutants of histone H3.1, H3.2, and H3.3 proteins. |
Constituents |
PBS, Glycerol, BSA |
PTM |
Unmodified |
Immunogen |
Synthetic peptide corresponding to human histone H3.3 K36M mutant |
Clonality |
Polyclonal |
Stability |
Stable for 12 months from date of receipt/reconstitution. |
Background |
K36M mutant of histone H3.3 is an "oncohistone" identified in more than 90% of chondroblastoma, a rare type of benign tumor caused by cartilage-producing cells. The mutant inhibits at least two H3K36 methyltransferases MMSET/WHSC1 and SETD2, triggering a depletion of H3K36 methylation and an increase of H3K27 trimethylation. H3.3K36M mutant proteins further alters expression of various genes including BMP2 that regulate oncogenesis and chondrogenesis. Chondrocytes expressing H3.3K36M exhibit several cancer-associated cellular phenotypes, including increased ability to form colonies, resistance to staurosporine-induced apoptosis, and defects in differentiation. |
Cellular Localization |
Nucleus |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.